Surrogate Endpoints: The Risks of Misleading Drug Approvals

This chapter examines the dangers associated with surrogate endpoints in drug approval, detailing instances where expected benefits did not materialize in real patient outcomes. It also introduces a public database created to evaluate the efficacy of drugs approved from 2013 to 2022, promoting greater transparency in the approval process.